Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for Non-segmental Vitiligo
2025-523266-24-00Phase 2Authorised
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pioglitazone in Vitiligo, sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: F-VASI50 at Week 16. Planned start Nov 2025; status: authorised.
02
Drugs
pioglitazone
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2025-523266-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523266-24-00.